This content is restricted.
Brief
"On November 27, 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved flortaucipir (Tauvid), a radiopharmaceutical product for adults with memory problems. This approval enables doctors to perform PET scans to determine if patients have abnormal forms of tau protein in their brain, which is associated with Alzheimer's disease."
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested